A newly developed antimicrobial agent, azithromycin (AZM), was evaluated in vitro and in vivo. The following results were obtained: 1) Antimicrobial activity: Minimal inhibitory concentrations (MICs) against 571 clinical isolates of 16 different species were determined, and compared with those of 4 other drugs, erythromycin, clarithromycin, roxithromycin and josamycin. AZM showed excellent antimicrobial activities against Haemophilus influenzae and Moraxella catarrhalis. The MICs of AZM against these bacteria were equal to or lower than those of the other drugs tested. 2) Clinical efficacy and adverse reactions: 11 patients with respiratory tract infections were treated with AZM. The overall efficacy rate was 90.9%(excellent in 3 cases, good in 7, fair in 1). No adverse reactions or abnormal laboratory findings were observed in any case, indicating that AZM is a safe agent.
|Number of pages||6|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 1995 Jan 1|
ASJC Scopus subject areas
- Pharmacology (medical)